Peter Ordentlich

6.7k total citations
67 papers, 4.2k citations indexed

About

Peter Ordentlich is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter Ordentlich has authored 67 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Molecular Biology, 23 papers in Oncology and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter Ordentlich's work include Histone Deacetylase Inhibitors Research (42 papers), Protein Degradation and Inhibitors (18 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Peter Ordentlich is often cited by papers focused on Histone Deacetylase Inhibitors Research (42 papers), Protein Degradation and Inhibitors (18 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Peter Ordentlich collaborates with scholars based in United States, Australia and France. Peter Ordentlich's co-authors include Ronald M. Evans, Michael Downes, Hung‐Ying Kao, Tom Kadesch, Richard A. Heyman, Yingzhuo Yan, Chris Kintner, Zhenyu Tang, Naoko Koyano‐Nakagawa and Wen Xie and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Peter Ordentlich

66 papers receiving 4.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Ordentlich United States 29 2.9k 1.2k 806 725 500 67 4.2k
Valentina Perissi United States 22 3.9k 1.3× 751 0.6× 690 0.9× 1.1k 1.5× 331 0.7× 37 5.0k
Carmé Caelles Spain 33 2.9k 1.0× 1.1k 0.9× 627 0.8× 470 0.6× 173 0.3× 56 4.2k
Linda M. Boxer United States 32 2.7k 0.9× 855 0.7× 609 0.8× 311 0.4× 328 0.7× 47 4.0k
Claudio Brancolini Italy 40 3.4k 1.2× 839 0.7× 1.1k 1.4× 259 0.4× 598 1.2× 103 5.1k
Michiaki Kohno Japan 35 3.1k 1.0× 846 0.7× 393 0.5× 291 0.4× 340 0.7× 92 4.5k
Rolf J. Craven United States 35 2.4k 0.8× 930 0.8× 425 0.5× 495 0.7× 198 0.4× 58 4.0k
Xuefen Le Bourhis France 39 2.9k 1.0× 743 0.6× 514 0.6× 259 0.4× 628 1.3× 88 4.2k
Esther Zwick Germany 11 2.3k 0.8× 1.2k 1.0× 350 0.4× 265 0.4× 415 0.8× 12 3.7k
A. Raymond Frackelton United States 28 2.5k 0.9× 853 0.7× 538 0.7× 1.6k 2.3× 248 0.5× 55 4.5k
Yasuhisa Fukui Japan 35 3.4k 1.2× 801 0.7× 459 0.6× 210 0.3× 251 0.5× 85 4.5k

Countries citing papers authored by Peter Ordentlich

Since Specialization
Citations

This map shows the geographic impact of Peter Ordentlich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Ordentlich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Ordentlich more than expected).

Fields of papers citing papers by Peter Ordentlich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Ordentlich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Ordentlich. The network helps show where Peter Ordentlich may publish in the future.

Co-authorship network of co-authors of Peter Ordentlich

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Ordentlich. A scholar is included among the top collaborators of Peter Ordentlich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Ordentlich. Peter Ordentlich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yang, Yue, Victor Sokolov, Xing Liu, et al.. (2024). Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft‐Versus‐Host Disease. Clinical Pharmacology & Therapeutics. 117(3). 704–715. 2 indexed citations
2.
Ordentlich, Peter. (2021). Clinical evaluation of colony-stimulating factor 1 receptor inhibitors. Seminars in Immunology. 54. 101514–101514. 32 indexed citations
3.
Hellmann, Matthew D., Pasi A. Jänne, Mateusz Opyrchal, et al.. (2020). Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy. Clinical Cancer Research. 27(4). 1019–1028. 83 indexed citations
4.
Hicks, Kristin C., Karin M. Knudson, Karin L. Lee, et al.. (2019). Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy. Clinical Cancer Research. 26(3). 704–716. 37 indexed citations
5.
Lee, Karin L., Stephen C. Benz, Kristin C. Hicks, et al.. (2019). Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy. Cancer Immunology Research. 7(8). 1359–1370. 20 indexed citations
6.
Sullivan, Ryan J., Stergios J. Moschos, Melissa L. Johnson, et al.. (2019). Abstract CT072: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy. Cancer Research. 79(13_Supplement). CT072–CT072. 31 indexed citations
7.
Hellmann, Matthew D., Pasi A. Jänne, Mateusz Opyrchal, et al.. (2018). OA05.01 Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy. Journal of Thoracic Oncology. 13(10). S330–S330. 17 indexed citations
8.
Simmons, John K., Aleksandra M. Michalowski, Wendy Dubois, et al.. (2017). Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation. Molecular Cancer Therapeutics. 16(9). 2008–2021. 27 indexed citations
9.
Lee, Jangsoon, Takahiro Kogawa, Peter Ordentlich, et al.. (2017). Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer. Clinical Cancer Research. 23(16). 4780–4792. 40 indexed citations
10.
Orillion, Ashley, Ayumi Hashimoto, Nur P. Damayanti, et al.. (2017). Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clinical Cancer Research. 23(17). 5187–5201. 291 indexed citations
11.
Merino, Vanessa F., Nguyen Nguyen, Kideok Jin, et al.. (2016). Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer. Cancer Research. 76(7). 2013–2024. 37 indexed citations
12.
Batlevi, Connie Lee, Yvette L. Kasamon, Peter Lee, et al.. (2016). ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma. Haematologica. 101(8). 968–975. 40 indexed citations
13.
14.
Lee, Jangsoon, et al.. (2014). A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Research and Treatment. 146(2). 259–272. 43 indexed citations
15.
LaFortune, Tiffany A., Peter Ordentlich, Dan Zhang, et al.. (2009). Synergistic Effect of Lapatinib and the Class 1 HDAC Inhibitor SNDX-275 in Breast Cancer.. Cancer Research. 69(24_Supplement). 3135–3135. 1 indexed citations
16.
Lee, Yi-Shan, Kian‐Huat Lim, Xingrong Guo, et al.. (2008). The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis. Cancer Research. 68(18). 7561–7569. 220 indexed citations
17.
Ordentlich, Peter, Yingzhuo Yan, Frank J. Gonzalez, et al.. (2002). A Natural Product That Lowers Cholesterol As an Antagonist Ligand for FXR. Science. 296(5573). 1703–1706. 437 indexed citations
18.
Shi, Yanhong, Michael Downes, Wen Xie, et al.. (2001). Sharp, an inducible cofactor that integrates nuclear receptor repression and activation. Genes & Development. 15(9). 1140–1151. 266 indexed citations
19.
Matsuno, Kenji, et al.. (1998). Human deltex is a conserved regulator of Notch signalling. Nature Genetics. 19(1). 74–78. 165 indexed citations
20.
Stevens, Sean, Peter Ordentlich, Ranjan Sen, & Tom Kadesch. (1996). HMG box-activating factors 1 and 2, two HMG box transcription factors that bind the human Ig heavy chain enhancer. The Journal of Immunology. 157(8). 3491–3498. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Valentina Perissi Breakdown of academic impact, for papers by Carmé Caelles Breakdown of academic impact, for papers by Linda M. Boxer Breakdown of academic impact, for papers by Claudio Brancolini Breakdown of academic impact, for papers by Michiaki Kohno Breakdown of academic impact, for papers by Rolf J. Craven Breakdown of academic impact, for papers by Xuefen Le Bourhis Breakdown of academic impact, for papers by Esther Zwick Breakdown of academic impact, for papers by A. Raymond Frackelton Breakdown of academic impact, for papers by Yasuhisa Fukui
Rankless by CCL
2026